EVLO vs. NAVB, SCPS, CMRA, GNCAQ, GNCA, ARDS, STAB, AMPE, CLVR, and EFTR
Should you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.
Evelo Biosciences vs. Its Competitors
Evelo Biosciences (NASDAQ:EVLO) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Evelo Biosciences has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Evelo Biosciences had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for Evelo Biosciences and 0 mentions for Navidea Biopharmaceuticals. Evelo Biosciences' average media sentiment score of 0.32 beat Navidea Biopharmaceuticals' score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media.
Navidea Biopharmaceuticals has higher revenue and earnings than Evelo Biosciences.
Summary
Navidea Biopharmaceuticals beats Evelo Biosciences on 4 of the 7 factors compared between the two stocks.
Get Evelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evelo Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:EVLO) was last updated on 7/2/2025 by MarketBeat.com Staff
